Leerink raised the firm’s price target on BeOne Medicines (ONC) to $367 from $364 and keeps an Outperform rating on the shares. The firm notes the company announced that the FDA has granted sonrotoclax accelerated approval in relapse/refractory mantle cell lymphoma. This is the first approval for sonrotoclax with additional trials ongoing in relapsed or refractory mantle cell lymphoma in combination with zanubrutinib, in R/R chronic lymphocytic leukemia / small lymphocytic lymphoma in combination with anti-CD20 antibodies, and treatment-naive chronic lymphocytic leukemia in combination with zanubrutinib.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines’ Beqalzi granted accelerated approval by FDA
- BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
- BeOne Medicines price target raised to $409 from $405 at Barclays
- BeOne Medicines price target raised to $420 from $410 at Guggenheim
- BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year